MedTrace Logo

Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.

NCT06383780 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2024-07-16

No results posted yet for this study

Summary

This is a prospective, open-label phase III clinical trial evaluating the efficacy and safety of the GP（Gemcitabine combined with cisplatin） regimen in combination with Tislelizumab versus the TPC（cisplatin, nab-paclitaxel and capecitabine）regimen in combination with Tislelizumab for the first-line treatment of Nasopharyngeal Carcinoma patients With Bone Metastasis.

Conditions

  • Nasopharyngeal Carcinoma

Interventions

DRUG

GP combined with Tislelizumab

Gemcitabine combined with cisplatin regimen combined with Tislelizumab

DRUG

TPC combined with Tislelizumab

cisplatin, nab-paclitaxel and capecitabine regimen combined with Tislelizumab

Sponsors & Collaborators

  • XIANG YANQUN

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-15
Primary Completion
2027-05-15
Completion
2029-05-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06383780 on ClinicalTrials.gov